AnnualReport2020

The Ambition Research &
Development 2020 Programmes
(ARD 2020)
ARD 2020
BIOPHARMACEUTICALS
The long-term Socio-economic development of the Centre-Val de Loire region, in a period of economic fragility,
depends on the strength and growth of quality research, development and innovation.
The ARD 2020 programmes, the Region Centre-Val de Loire’s initiative to implement the EU Smart
Specialisation Strategy, have been designed to generate socio-economic impacts by providing support to
create strong regional research and develop centres of international scale, stimulate innovation, job creation
and socioeconomic dynamism in the territory.
Through these large research programmes, the Centre-Val de Loire Regional Council supports the
strengthening of quality research in five targeted strategic domains to foster the development of world-class
poles to enhance research and innovation activity in the region:
ARD 2020 Biomédicaments
(biopharmaceuticals),
ARD 2020 Cosmetosciences (cosmetics),
ARD 2020 LAVOISIER (renewable energies),
LE STUDIUM stands as the official partner of these five regional ARD 2020 programmes, leading on the
internationalisation dynamic by providing expertise and services to recruit international experienced
researchers and organise actions and events to boost international scientific exchanges and collaborations
and valorize research works carried out in the region.
ARD 2020 PIVOTS (environmental
engineering),
ARD 2020 Intelligence des Patrimoines
(Cultural and Natural).
A drug is any substance or composition presented as having properties for treating,
preventing or diagnosing disease in humans or animals. Whereas BIOPHARMACEUTICALS
in the strict sense of the term, are molecules that have the characteristic of being
produced from living organisms or their cellular components. These molecules are
intermediate between chemical drugs and organisms’ intrinsic biologics. By definition, a
biopharmaceutical is any drug whose active substance is a therapeutic macromolecule
produced by living organisms. Biopharmaceuticals are overwhelmingly protein-based,
mainly represented by non-living vaccines, therapeutic antibodies, enzymes, protein
hormones and growth factors. As proteins, their injection is today mandatory by injection.
The proportion of biopharmaceuticals in the drug market has dramatically increased
over the past decade. The Centre-Val de Loire region is at the cutting edge of research
in the pharmaceutical sector and has included the development of biopharmaceuticals
in its smart specialisation strategy for the period 2013-2020. The regional government
has injected a strong financial support in research to facilitate innovative inter-sectorial
industrial development and partnerships for socioeconomic development beyond 2020.
The ARD 2020 Biopharmaceuticals programme aimed to further develop and strengthen
the Centre-Val de Loire regional biopharmaceuticals industry by capitalising on the
recognised capabilities of the multidisciplinarity research teams from the regional
research institutions in the view to:
Develop a flagship research and development pole on
biopharmaceuticals in the Centre-Val de Loire region.
Configure the biopharmaceuticals field by inter-sectorial development
and innovation in the pharmacy/health sectors through start-ups,
SMEs (Small and Medium Enterprises) including established local and
regional based multinational companies.
Smart Loire Valley Programmes 2020
Promote the transfer of technologies/competences to existing and new
businesses.
Support the development of new competences for the sector.
The Biopharmaceuticals Programme creates a dynamic, mobilising actors in
the pharmaceutical sector, from fundamental research to production, to jointly
develop the tomorrow’s biopharmaceutical treatments in the Centre-Val de
Loire region. It focuses on the design and biosynthesis of biomolecules for
preclinical and clinical development by including the search for synergies with
conventional chemically synthesised drugs. A number of innovative projects
including academic and industrial partnerships covering a wide spectrum of
biological molecules and domains are directly financed to bring immediate
outcomes: vaccines, therapeutic antibodies, nucleic acids, lipoproteins, bioproduction
of medicines…
Since 2014, LE STUDIUM has recruited nine scientists for long-term residencies
who have highly contributed to the objectives of the programme. A new phase
of development is under preparation for the period 2021-2024.
ARD 2020 2020
12
13